Stellantis announced a reset of its electrification plan, shifting away from an all electric focus toward a broader mix of hybrid and internal combustion models. The company recorded a €22.2b reset ...

Olema Pharmaceuticals (OLMA) is back in focus after Roche’s Phase 3 breast cancer trial for giredestrant missed its primary endpoint, a setback that coincided with a sharp 41% drop in Olema’s share ...